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Abstract. Rapid diagnostic tests (RDTs) play a critical role in malaria diagnosis and control. The emergence of
Plasmodium falciparum parasites that can evade detection by RDTs threatens control and elimination efforts. These
parasites lack or have altered genes encoding histidine-rich proteins (HRPs) 2 and 3, the antigens recognized by HRP2-
based RDTs. Surveillance of such parasites is dependent on identifying false-negative RDT results among suspected
malaria cases, a task mademore challenging during the current pandemic because of the overlap of symptoms between
malaria andCOVID-19, particularly in areasof lowmalaria transmission. Here,we shareour perspective on the emergence
of P. falciparum parasites lacking HRP2 and HRP3, and the surveillance needed to identify them amid the COVID-19
pandemic.
INTRODUCTION
A previously unknown coronavirus was identified as the
causative agent of serious respiratory illness in January 2020
in Wuhan, China. The WHO named the virus SARS-CoV-2,
and the disease was named COVID-19.1 World leaders have
mobilized their resources to fight the pandemic, which has
caused more than 7 million cases and more than 400,000
deaths worldwide as of June 8, 2020. In Africa, more than
200,000 COVID-19 cases and 5,000 deaths were reported in
57 countries as of that date. Whereas the world is focused on
COVID-19 and resources are diverted to contain the pandemic,
other infectious diseases such asmalaria, tuberculosis, andHIV/
AIDS continue to affect millions, particularly in Africa.
MALARIA—ONE OF THE LEADING CAUSES OF DEATH
IN AFRICA
In 2019, the WHO reported an estimated 228 million cases
of malaria worldwide, mostly in Africa (213 million cases), and
405,000deaths,most ofwhichwere in theWHOAfrican region
(94%).2 Progress has been made in reducing the number of
cases and deaths associated with effective vector control, the
deployment of rapid diagnostic tests (RDTs), and effective,
accessible treatment. The COVID-19 pandemic threatens to
reverse these achievements because of erosion of health
systems and disruption of malaria control and elimination
programs. The WHO considers a worst-case scenario, with
distribution of insecticide-treated nets for 2020 canceled and
a reduction in effective malaria treatment by 75%, leading to a
23% increase in malaria cases and a 102% increase in
deaths.3 Iran, for example, having reported zero indigenous
malaria cases for the first time in 2018, is severely impacted
across its entire health system by the pandemic, with high
numbers of confirmed COVID-19 cases and deaths posing a
threat to the sustainability of its malaria-free status.
MALARIA DIAGNOSIS
Since 2010, WHO malaria treatment guidelines have in-
cluded recommendations to test all suspected cases by mi-
croscopy or RDTs. Both can provide definitive malaria
diagnosis within minutes. Because accurate microscopic
examination requires expertise and is not always available in
remote areas, RDTs are increasingly used, particularly at the
community level and in primary healthcare facilities. Histidine-
rich protein 2 (HRP2)–based RDTs detect only Plasmodium
falciparum, whereas alternatives that detect lactate de-
hydrogenase (LDH) or aldolase are used for P. falciparum only
(Pf-LDH), Plasmodium vivax only (Pv-LDH), all species other
than P. falciparum (Pvom-pLDH), or all Plasmodium species
(pan-LDH; aldolase). Rapid diagnostic tests that detect HRP2
are the most widely used tests against P. falciparum, as RDTs
that detect LDH and aldolase are less sensitive and more
susceptible to degradation from heat and humidity during
transport and storage.4,5 Some RDTs in use detect a combi-
nation of antigens such as Pf-HRP2/Pf-LDH, Pf-HRP2/pan-
LDH, or Pf-HRP2/Pv-LDH (Table 1).
THE EMERGENCE OF “DIAGNOSTIC RESISTANCE” IN
MALARIA PARASITES
“Diagnostic resistance” is due to the emergence of
P. falciparum strains that escape RDT detection because of
deletion of genes encoding HRP2 and HRP3, the antigens
recognized by the most commonly used RDTs. Plasmodium
falciparum parasites with these deletions first emerged in
South America6 andwere subsequently reported in Southeast
Asia and Africa.7 Our team has described their circulation in
Kenya,8 Tanzania,9 and Uganda.10 Our most recent data from
travelers returning to theUnited Kingdomwithmalaria provide
evidence for such parasites in Somalia and South Sudan, and
suggests theyalso circulate inEritrea, Ethiopia, Kenya,Sudan,
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and Uganda.11 Countries with a high prevalence of these
deletions, such as Peru and Eritrea, have already removed
HRP2-based RDTs from their diagnostic policies, but alter-
natives are scarce,more expensive, and require compromises
in sensitivity.
IS IT MALARIA OR COVID-19?
The most common symptoms of SARS-CoV-2 infection
have been reported as fever, cough, and shortness of
breath.12 The WHO defines a suspected COVID-19 case as a
patient with acute respiratory illness (fever and at least one
sign/symptom of respiratory disease such as cough) in the
absence of an alternative diagnosis that fully explains the clin-
ical presentation.12 However, not all virus-positive COVID-19
patients exhibit respiratory symptoms, and the spectrum of
presentation is now understood to be broad. This is further
complicated inmalaria-endemic countries, where fever is also
the main symptom of malaria. If a patient shows symptoms
common to both COVID-19 and malaria, an obvious solution
would be to rule out malaria infection using an RDT, a strategy
used to rapidly triage malaria patients during theWest African
Ebola virus outbreak in 2016–2017.13,14 However, as de-
scribed earlier, the results of HRP2-RDTs are no longer
completely reliable in some parts of the world, particularly in
low transmission settings.
WHAT NEEDS TO BE DONE?
The WHO has recently published a document entitled
“Tailoring malaria interventions in the COVID-19 response.”17
The document emphasizes the continued use of RDTs for
suspectedmalaria cases after rulingout other possible causes
of fever as per national guidelines. The document recom-
mends that, under special circumstances, to overcome chal-
lenges that have arisen because of the COVID-19 pandemic
such as supply chain disruption for RDTs, absenteeism of
health workers, shortage of personal protective equipment,
and the ambiguity of fever symptoms, a malaria diagnosis be
considered for all fever cases in endemic countries. This ap-
proach, under the special circumstances mentioned earlier,
could ensure treatment of RDT-negativemalaria patients and,
at the population level, potentially curtail the spread of
P. falciparum parasites carrying the hrp2/3 deletion. Although
efforts to control hrp2/3-deleted parasites benefit from the
presumptive treatment of malaria cases, a long-term sus-
tainable solution should be in place to ensure the continued
surveillance and control of such parasite strains beyond the
COVID-19 pandemic.
The safety of patients must be taken into consideration,
especially in remote primary health centers, which are heavily
dependent on RDTs for malaria diagnosis because of the
absence of microscopy. Careful management will be required
when treating COVID-19–suspected patients with artemisinin
combination therapies (ACTs), which are known to cause
corrected QT interval prolongation in some patients.18–21
Despite the lack of an established effective treatment for
COVID-19, drugs such as chloroquine, hydroxychloroquine,
and azithromycin have been widely used,22 and these can
also cause corrected QT interval prolongation, even at doses
regarded as safe.20,23 Administration of these drugs to
COVID-19 patients who have already received a presumptive
dose of ACTs because of febrile presentation may then lead
to cardiac complications.
The WHO has called for ministries of health and national
malaria control programs to ensure thatmalaria control efforts
are not hampered while tackling the COVID-19 response.17
Malaria parasites with hrp2/3 deletions are now known to be
present in 31 countries, but the epidemiology of this problem
is not sufficiently well documented to permit a targeted re-
sponse.24 In low malaria transmission areas, where age-
groupswith symptomsofmalaria andCOVID-19 are expected
to overlap, investigation of fevers is challenging because of
the possibility of hrp2/3 deletions, particularly if only HRP2-
basedRDTs are used for diagnosis. An alternative approach is
to conduct systematic surveillance of hrp2/3 deletions in pri-
ority countries using a non–HRP2-based RDT. A template
protocol developed by the WHO is now available to guide the
surveillance of hrp2/3 deletions.25 The protocol recommends
the use of diagnostics recognizing Pf-HRP2 and Pf-LDH or
microscopy to identify suspected hrp2/3 deletions.
Thediagnosticchallengescausedby theCOVID-19pandemic
offer an ideal opportunity to scale up the surveillance for hrp2/3
diagnostic resistance in P. falciparum, initially by rapid adoption
of the WHO surveillance protocol. A variety of RDTs for SARS-
CoV-2 have emerged, and a similar effort against malaria could
provide an alternative to HRP2-based RDT in the medium term,
particularly if they can be developed in endemic settings. Efforts
should focus on antigens that aremore sensitive and heat stable
than the non-HRP2 tests currently available.
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TABLE 1
COVID-19 cases andmalaria diagnosis method (in community setting and primary health facilities) in selected countries where hrp2/3 deletion has
been reported
Country COVID-19 cases* Malaria diagnosis method2 Estimated hrp2/3 gene deletion prevalence† Reference for hrp2/3 deletion
Eritrea 41 Pan-LDH RDT‡ 62% 7,11
Ethiopia > 500 Pf-HRP2/Pv-LDH RDT Not known 11,15
Kenya > 1,000 Pf-HRP2 RDT < 5% 8
Somalia > 2,000 Pf-HRP2/Pan-LDH RDT Not known 11
Sudan > 3,000 Pf-HRP2/Pv-LDH RDT 3–5% 11,16
South Sudan > 400 Pf-HRP2 RDT 5–10% 11
Tanzania > 500 Pf-HRP2/Pan-LDH RDT 1% 10, 11
LDH = lactate dehydrogenase; RDT = rapid diagnostic test.
* As of June 8, 2020.
†Based on sporadic evidence.
‡Recently changed from Pf-HRP2/Pv-LDH RDT to Pan-LDH RDT = Plasmodium-lactate dehydrogenase; Pv-LDH = P. vivax-LDH.
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